<?xml version="1.0" encoding="UTF-8"?>
<p class="p">For these reasons, fungal infections are still considered a serious problem worldwide that require effective therapeutic strategies. The most common antifungal agents used nowadays include fluconazole, amphotericin B and terbinafine. Nevertheless, these drugs have several reported adverse effects, such as nephrotoxicity and hepatotoxicity. Furthermore, they show a slow response in immunocompromised individuals (
 <xref rid="B21" ref-type="bibr" class="xref">Khan and Ahmad, 2011</xref>) and have several therapeutic limitations, such as drug interactions, insufficient bioavailability and a fungistatic mechanism of action. In addition, development of resistance as well as innate resistance by emerging species have also been reported (
 <xref rid="B24" ref-type="bibr" class="xref">Pfaller, 2012</xref>). Therefore, actual antifungal therapies are far from acceptable reinforcing the urgent need for the development of effective antifungal drugs.
</p>
